Valneva SE (NASDAQ:VALN) Sees Large Decline in Short Interest

Valneva SE (NASDAQ:VALN) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 14,500 shares, a decline of 69.9% from the October 31st total of 48,200 shares. Based on an average daily volume of 20,100 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price target on Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

Valneva Stock Performance

VALN opened at $3.99 on Thursday. The stock has a market cap of $324.19 million, a PE ratio of -30.46 and a beta of 2.17. Valneva has a 1 year low of $3.93 and a 1 year high of $11.96. The stock’s 50 day simple moving average is $5.54 and its 200-day simple moving average is $6.87. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its stake in Valneva stock. AlphaCentric Advisors LLC boosted its holdings in Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,252 shares of the company’s stock after acquiring an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned 0.13% of Valneva worth $649,000 at the end of the most recent quarter. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.